Group | PC | FC | HY | SP | SA | HI |
---|---|---|---|---|---|---|
Females, 0.2 mg/kg | 696 ± 27.1 | 552 ± 36.2 | 317 ± 21.7 | 413 ± 25.6 | 356 ± 27.3 | 562 ± 29.0 |
(100) | (79) | (46) | (59) | (51) | (81) | |
Males, 0.2 mg/kg | 31 ± 2.5 | 33 ± 4.9 | 14 ± 1.7 | 19 ± 1.7 | 25 ± 4.2 | 24 ± 2.7 |
(100) | (110) | (44) | (62) | (80) | (79) | |
Females, 1.0 mg/kg | 2455 ± 141 | 2201 ± 213 | 1101 ± 60 | 1634 ± 66 | 1391 ± 130 | 2286 ± 154 |
(100) | (90) | (45) | (67) | (57) | (93) | |
Males, 1.0 mg/kg | 108 ± 7.9 | 95 ± 8.7 | 49 ± 7.8 | 61 ± 6.6 | 50 ± 14.1 | 77 ± 6.6 |
(100) | (88) | (46) | (56) | (47) | (72) |
The concentrations of MK-801 (mean ± S.E.M.) (pmol/g) in six different brain regions around 3 to 5 h after i.p. injection. The dissection procedure was modified from Glowinski and Iversen (1966). Male rats that received either low (0.2 mg/kg) or high (1.0 mg/kg) doses of MK-801 had 20 to 25 times lower brains concentrations in all brain regions when compared with female rats that received the same i.p. dose of MK-801 (p < .0001 for all groups). The values within parentheses represent percent MK-801 concentration when compared with PC within the same group.
PC, parietal cortex; FC, frontal cortex; HY, hypothalamus; SP, striatum posterior; SA, striatum anterior; HI, hippocampus.